LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
30
11
2021
accepted:
14
02
2022
revised:
04
02
2022
pubmed:
26
3
2022
medline:
6
5
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0-1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1-20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2-36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9-5.6) and 12.4 months (95% CI: 10.3-NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
Identifiants
pubmed: 35332278
doi: 10.1038/s41375-022-01531-2
pii: 10.1038/s41375-022-01531-2
pmc: PMC9061296
doi:
Substances chimiques
Proteasome Inhibitors
0
Dexamethasone
7S5I7G3JQL
Banques de données
ClinicalTrials.gov
['NCT04035226']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1371-1376Informations de copyright
© 2022. The Author(s).
Références
Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26.
doi: 10.1038/s41408-018-0065-8
Franssen LE, Mutis T, Lokhorst HM, van de Donk N. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:2040620718822660.
doi: 10.1177/2040620718822660
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75.
doi: 10.1038/s41375-019-0435-7
Durie BG, Miguel JF, Blade J, Rajkumar SV. Clarification of the definition of complete response in multiple myeloma. Leukemia. 2015;29:2416–7.
doi: 10.1038/leu.2015.290
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.
doi: 10.1016/S1470-2045(16)30206-6
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5.
doi: 10.1182/blood-2010-10-299487
Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–48.
doi: 10.1038/leu.2017.138
Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, et al. Analysis of real-world data on overall survival in multiple myeloma patients with >/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355–61.
doi: 10.1634/theoncologist.2016-0104
Costa LJ, Lin Y, Martin TG, Chhabra S, Usmani SZ, Jagannath S, et al. Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma. J Clin Oncol. 2021;39:8030–30.
doi: 10.1200/JCO.2021.39.15_suppl.8030
Blade Creixenti J, Mateos M-V, Oriol A, Larocca A, Cavo M, Rodríguez-Otero P. et al. HORIZON (OP-106) Versus MAMMOTH: an indirect comparison of efficacy outcomes for patients with relapsed/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus eexamethasone versus conventional agents. Blood. 2020;136:2–4.
doi: 10.1182/blood-2020-137164